Inactivation of the tyrosine phosphatase SHP-2 drives vascular dysfunction in SepsisResearch in context
Yvonn Heun,
Joachim Pircher,
Thomas Czermak,
Philipp Bluem,
Georg Hupel,
Monica Bohmer,
Bjoern F. Kraemer,
Kristin Pogoda,
Alexander Pfeifer,
Markus Woernle,
Andrea Ribeiro,
Max Hübner,
Simone Kreth,
Ralf A. Claus,
Sebastian Weis,
Luisa Ungelenk,
Florian Krötz,
Ulrich Pohl,
Hanna Mannell
Affiliations
Yvonn Heun
Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr 27, München 81377, Germany; Biomedical Center, Ludwig-Maximilians-University, Großhaderner Str. 9, Planegg 82152, Germany
Joachim Pircher
Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Marchioninistrasse 15, Munich 81377, Germany; DZHK (German Center for Cardiovascular Research) partner site Munich Heart Alliance, Munich, Germany
Thomas Czermak
Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Marchioninistrasse 15, Munich 81377, Germany
Philipp Bluem
Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr 27, München 81377, Germany; Biomedical Center, Ludwig-Maximilians-University, Großhaderner Str. 9, Planegg 82152, Germany
Georg Hupel
Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr 27, München 81377, Germany; Biomedical Center, Ludwig-Maximilians-University, Großhaderner Str. 9, Planegg 82152, Germany
Monica Bohmer
Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr 27, München 81377, Germany; Biomedical Center, Ludwig-Maximilians-University, Großhaderner Str. 9, Planegg 82152, Germany
Bjoern F. Kraemer
Medizinische Klinik und Poliklinik I, Klinikum der Universität München, Marchioninistrasse 15, Munich 81377, Germany
Kristin Pogoda
Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr 27, München 81377, Germany; Biomedical Center, Ludwig-Maximilians-University, Großhaderner Str. 9, Planegg 82152, Germany
Alexander Pfeifer
Institute of Pharmacology and Toxicology, Biomedical Center University of Bonn, Sigmund-Freud-Straße 25, Bonn 53105, Germany
Markus Woernle
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstr.1, Munich 80336, Germany
Andrea Ribeiro
Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstr.1, Munich 80336, Germany
Max Hübner
Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr 27, München 81377, Germany; Department of Anesthesiology, Klinikum der Universität München, Marchioninistraße 15, München 81377, Germany
Simone Kreth
Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr 27, München 81377, Germany; Department of Anesthesiology, Klinikum der Universität München, Marchioninistraße 15, München 81377, Germany
Ralf A. Claus
Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena 07747, Germany
Sebastian Weis
Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena 07747, Germany; Institute for Infectious Disease and Infection Control, Jena University Hospital, Jena 07747, Germany; Center for Sepsis Control and Care, Jena University Hospital, Jena 07747, Germany
Luisa Ungelenk
Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena 07747, Germany
Florian Krötz
Interventional Cardiology, Starnberg Community Hospital, Oßwaldstr. 1, Starnberg 82319, Germany
Ulrich Pohl
Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr 27, München 81377, Germany; Biomedical Center, Ludwig-Maximilians-University, Großhaderner Str. 9, Planegg 82152, Germany; DZHK (German Center for Cardiovascular Research) partner site Munich Heart Alliance, Munich, Germany; Munich Cluster for Systems Neurology, (SyNergy), Munich, Germany
Hanna Mannell
Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr 27, München 81377, Germany; Biomedical Center, Ludwig-Maximilians-University, Großhaderner Str. 9, Planegg 82152, Germany; Hospital Pharmacy, University Hospital, Ludwig-Maximilians-University, Marchioninistraße 15, München 81377, Germany; DZHK (German Center for Cardiovascular Research) partner site Munich Heart Alliance, Munich, Germany; Corresponding author at: Walter Brendel Centre of Experimental Medicine, University Hospital, Ludwig-Maximilians-University, Marchioninistr. 27, München 81377, Germany.
Background: Sepsis, the most severe form of infection, involves endothelial dysfunction which contributes to organ failure. To improve therapeutic prospects, elucidation of molecular mechanisms underlying endothelial vascular failure is of essence. Methods: Polymicrobial contamination induced sepsis mouse model and primary endothelial cells incubated with sepsis serum were used to study SHP-2 in sepsis-induced endothelial inflammation. SHP-2 activity was assessed by dephosphorylation of pNPP, ROS production was measured by DCF oxidation and protein interactions were assessed by proximity ligation assay. Vascular inflammation was studied in the mouse cremaster model and in an in vitro flow assay. Findings: We identified ROS-dependent inactivation of the tyrosine phosphatase SHP-2 to be decisive for endothelial activation in sepsis. Using in vivo and in vitro sepsis models, we observed a significant reduction of endothelial SHP-2 activity, accompanied by enhanced adhesion molecule expression. The impaired SHP-2 activity was restored by ROS inhibitors and an IL-1 receptor antagonist. SHP-2 activity inversely correlated with the adhesive phenotype of endothelial cells exposed to IL-1β as well as sepsis serum via p38 MAPK and NF-κB. In vivo, SHP-2 inhibition accelerated IL-1β-induced leukocyte adhesion, extravasation and vascular permeability. Mechanistically, SHP-2 directly interacts with the IL-1R1 adaptor protein MyD88 via its tyrosine 257, resulting in reduced binding of p85/PI3-K to MyD88. Interpretation: Our data show that SHP-2 inactivation by ROS in sepsis releases a protective break, resulting in endothelial activation. Fund: German Research Foundation, LMU Mentoring excellence and FöFoLe Programme, Verein zur Förderung von Wissenschaft und Forschung, German Ministry of Education and Research. Keywords: Endothelial cells, IL-1β, MyD88, ROS, SHP-2, Sepsis